COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...

Descrición completa

Detalles Bibliográficos

Principais autores:	E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
Formato:	Artigo
Idioma:	Russo
Publicado:	IRBIS LLC 2017-08-01
Series:	Фармакоэкономика
Assuntos:	chronic obstructive pulmonary disease copd long-acting beta-agonists laba long-acting anticholinergics laac vilantererol umeclidinum bromide olodaterol tiotropium bromide fixed combination cost minimization analysis cost-effectiveness analysis budget impact analysis
Acceso en liña:	https://www.pharmacoeconomics.ru/jour/article/view/196
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!